Personal CFO Solutions LLC Increases Position in Illumina, Inc. (NASDAQ:ILMN)

Personal CFO Solutions LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 9.2% in the 4th quarter, Holdings Channel reports. The fund owned 1,789 shares of the life sciences company’s stock after buying an additional 150 shares during the quarter. Personal CFO Solutions LLC’s holdings in Illumina were worth $239,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Empowered Funds LLC grew its position in Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Bank of Stockton grew its position in Illumina by 3.8% in the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after acquiring an additional 80 shares in the last quarter. Caprock Group LLC grew its position in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares in the last quarter. Stephens Inc. AR grew its position in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after acquiring an additional 90 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its position in Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank of Canada cut their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $100.00 in a research report on Monday, February 10th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Guggenheim cut their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Price Performance

ILMN stock opened at $85.97 on Tuesday. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a market cap of $13.62 billion, a P/E ratio of -11.19, a PEG ratio of 1.60 and a beta of 1.17. The firm has a 50-day moving average of $117.43 and a 200 day moving average of $131.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.